Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Rezivertinib with Itraconazole and Rifampicin in Healthy Volunteers
NCT04135833Phase 1Completed
- Sponsor
- Beta Pharma
- Start
- Dec 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rezivertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Beta Pharma. Primary endpoints: Maximum Plasma Concentration at Day 25 and Area Under the Curve (0-last) at Day 25. Started Dec 2019; status: completed.
02
Drugs
rezivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04135833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135833.